Group 1 - The Hong Kong innovative drug index has fallen over 20% since September, with unprofitable companies experiencing declines exceeding 40% [1][3] - There is a stark contrast between the increase in IPOs and financing amounts and the continuous drop in stock prices, raising questions about the investment logic in innovative drugs [3][4] - The core viewpoint suggests that while the long-term trend of the industry remains unchanged, the pricing anchor must be adjusted, shifting from paying for "dreams" to valuing "reality" [4] Group 2 - A two-step strategy is proposed: first, to avoid companies with single pipelines, depleted cash flows, and those relying solely on narratives; second, to focus on leading companies with significant products nearing commercialization and healthier cash flows [5] - The current market situation prompts investors to consider whether the innovative drug sector has reached a "golden pit" for investment or is trapped in a "value trap" after a 40% decline [5]
创新药跌出“黄金坑”还是“万人坑”？基金经理吵翻了！
Sou Hu Cai Jing·2025-12-29 01:33